Tag: Seagen

Philadelphia-based Medicus Oncology gains global development and commercialization rights to PF-08046031 (CD228V), a melanotransferrin-targeted antibody-drug conjugate (ADC) originating from Pfizer's Seagen acquisition, as Pfizer retains a co-development role, milestone eligibility, and tiered royalties.

The emergence of degrader-antibody conjugates or DACs has attracted much attention, with a potential to transform the precision medicine landscape.

During the upcoming 2024 annual meeting of the American Society of Clinical Oncology (ASCO) Annual Meeting, been held from May 31st - June 4th, Astellas...

What to Expect at World ADC 2024 in London

The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for tisotumab vedotin (Tivdak®; Genmab and Pfizer) for the treatment of patients with recurrent or metastatic cervical cancer.

Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...

Zai Lab, a patient focused, global biopharma company committed to driving the next wave of healthcare innovation confirmed that it had signed an exclusive collaboration and...

Seagen and Sanofi today confirmed that the companies have agreed to fund and commercialize the development of 3 antibody-drug Conjugates or ADCs designed to enhance...

Preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (Tivdak®; Seagen and Genmab) as a monotherapy in patients...

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved enfortumab vedotin (Padcev®; Astellas Pharma and Seagen) for the treatment of radically unresectable urothelial...